Kailera begins Phase 3 testing of ribupatide, including a head-to-head with semaglutide
A new experimental obesity drug is entering late-stage testing, and one of its trials will measure it directly against semaglutide, the medicine in Ozempic and Wegovy.
Kailera Therapeutics has opened its global KaiNETIC Phase 3 program for ribupatide, an experimental obesity drug, and the first of three late-stage trials is enrolling participants. One of those studies is a head-to-head comparison against semaglutide, the medicine sold as Ozempic, Wegovy and Rybelsus [2].
What the two registered trials test
Two ribupatide studies are listed on ClinicalTrials.gov. The first, NCT07284979, is titled "Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes" [2]. It has three kinds of treatment groups: once-weekly ribupatide, semaglutide, and placebo.
The second, NCT07284875, studies ribupatide in people who have obesity or are overweight and also have weight-related health conditions, and it also excludes people with diabetes [1]. Neither listing describes how many people the studies aim to enroll, where the sites are, or how long each trial will run.
In the comparison study, semaglutide is listed as an active comparator, which means the people in that group receive an approved, effective medicine rather than an inactive placebo [2].
Where the drug comes from
Ribupatide is also known as KAI-9531. Kailera licensed it from Jiangsu Hengrui Pharmaceuticals of China, where it was developed under the name HRS9531. The KaiNETIC program is described as the most advanced of the recent deals that move obesity drugs from Chinese developers into Western markets.
What has not been reported
Several things a patient might want to know are not yet available. The target number of participants, the start and completion dates, and the expected date for results have not been disclosed in the registry listings [1][2]. It has also not been reported whether ribupatide is given as an injection or as a pill; the listings describe once-weekly dosing but do not specify the form [2]. Kailera has not said whether or when it plans to seek FDA approval, and no price or insurance information exists for a drug that is not approved.
Why it matters for patients
The trials matter because they compare a new drug against a drug that millions of Americans already take. If ribupatide performs as well as or better than semaglutide on weight loss and side effects, it could become another option in a market where demand has repeatedly outpaced supply.
Competition at that scale can affect supply, insurance coverage and pricing over time, though no company has made commitments about cost for an unapproved drug.
For now, nothing changes for people already taking semaglutide or tirzepatide, the medicine in Mounjaro and Zepbound. Trial results typically take years, and a registered trial is not evidence that a drug works. The two studies listed so far exclude people with diabetes [1][2], so their results will not answer questions about how ribupatide performs in people with type 2 diabetes. Participants who are randomly assigned to the placebo group in the comparison study will not receive an active weight-loss drug during that period [2].
What happens next
Enrollment in the first KaiNETIC trial is under way as of December 18, 2025. Details of the third Phase 3 trial in the program have not been posted. No dates for reporting results have been announced.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.